Mechanisms underlying relaxation of rabbit aorta by BAY 41-2272, a nitric oxide-independent soluble guanylate cyclase activator

被引:38
|
作者
Priviero, FBM [1 ]
Baracat, JS [1 ]
Teixeira, CE [1 ]
Claudino, MA [1 ]
De Nucci, G [1 ]
Antunes, E [1 ]
机构
[1] UNICAMP, Fac Med Sci, Dept Pharmacol, BR-13084971 Campinas, SP, Brazil
关键词
aorta; BAY; 41-2272; IH-[1,2,4]oxadiazolo[4, 3-a]quinoxalin-1-one; nitric oxide; sildenafil; soluble guanylate cyclase;
D O I
10.1111/j.1440-1681.2005.04262.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. The compound BAY 41-2272 (5-cyclopropyl-2-[1-(2fluoro-benzyi)-1H-pyrazolo[3,4-b]pyridin-3-yl]-pyrimidin-4- ylamine) has been described as a potent, nitric oxide (NO)independent, stimulator of soluble guanylate cyclase. In the present study, the mechanisms underlying the relaxant effect of BAY 41-2272 in endothelium-intact and -denuded precontracted rabbit aortic rings were investigated. 2. Male New Zealand white rabbits were anaesthetized with pentobarbital sodium. Aortic rings were transferred to 10 mL organ baths containing oxygenated and warmed Krebs' solution. Tissues were connected to force-displacement transducers and changes in isometric force were recorded. Aortic rings were precontracted submaximally with phenylephrine (1 mu mol/L). 3. The addition of BAY 41-2272 (0.01-10 mu mol/L) to the organ bath produced concentration-dependent relaxations of the aortic rings with a higher potency in endothelium-intact (pEC(50) 6.59 +/- 0.05) compared with endothelium-denuded (pEC(50) 6.19 +/- 0.04; P < 0.05) preparations. No differences in maximal responses were observed in either preparation. The NO synthesis inhibitor N-G-nitro-L-arginine methyl ester (100 mu mol/L) produced a 2.1-fold rightward shift in endothelium-intact (P < 0.01) rings, but had no effect in endothelium-denuded rings. The soluble guanylate cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ; 1 mu mol/L) caused significant rightward shifts of the concentration-response curves to BAY 41-2272 of 4.9- and 2.6-fold in endothelium-intact and -denuded rings, respectively. The phosphodiesterase-5 inhibitor sildenafil (0.1 mu mol/L) significantly potentiated the relaxant effects of BAY 41-2272 in both endothelium-intact and -denuded rings. 4. At 1 mu mol/L, BAY 41-2272 significantly elevated the aortic cGMP content above basal levels in both endothelium-intact and -denuded rings. Furthermore, ODQ reduced BAY 41-2272-elicited increases in cGMP content by 17 and 90% in endothelium-intact and -denuded rings, respectively (P < 0.01). 5. In conclusion, BAY 41-2272 potently relaxes endothelium-intact and -denuded rabbit aortic rings. The basal release of endothelium-derived NO enhances BAY 41-2272-induced relaxations, suggesting a synergistic effect of BAY 412272 and NO on soluble guanylate cyclase. In addition, the endothelium-independent relaxation involves both GMP-dependent and -independent mechanisms.
引用
收藏
页码:728 / 734
页数:7
相关论文
共 50 条
  • [41] YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice
    Teng, CM
    Wu, CC
    Ko, FN
    Lee, FY
    Kuo, SC
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 320 (2-3) : 161 - 166
  • [42] BAY 41-2272, a direct activator of soluble guanylate cyclase, reduces right ventricular hypertrophy and prevents pulmonary vascular remodeling during chronic hypoxia in neonatal rats
    Deruelle, Philippe
    Balasubramaniam, Vivek
    Kunig, Anette M.
    Seedorf, Gregory J.
    Markham, Neil E.
    Abman, Steven H.
    BIOLOGY OF THE NEONATE, 2006, 90 (02): : 135 - 144
  • [43] Cardiorenal actions of the novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure in comparison to nitroglycerin
    Boerrigter, G
    Costello-Boerrigter, LC
    Lapp, H
    Cataliotti, A
    Tsuruda, T
    Harty, GJ
    Stasch, JP
    Burnett, JC
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (06) : 253A - 254A
  • [44] The soluble guanylyl cyclase stimulator BAY 41-2272 increases differentiation and function of brown adipocytes
    Jennifer Etzrodt
    Linda S Hoffmann
    Andreas Friebe
    Alexander Pfeifer
    BMC Pharmacology and Toxicology, 14 (Suppl 1)
  • [45] Different sensitivities of soluble guanylyl cyclase isoforms towards the novel drug BAY 41-2272
    Koglin, M
    Behrends, S
    Scholz, H
    Stasch, JP
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2002, 365 : R41 - R41
  • [46] Cytokines decrease soluble guanylate cyclase subunit mRNA levels via a nitric oxide-independent mechanism
    Filippov, G
    Bloch, KD
    CIRCULATION, 1997, 96 (08) : 4072 - 4072
  • [47] YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits the spontaneous contractions of isolated pregnant rat myometrium
    Cetin, A
    Kaya, T
    Demirkoprulu, N
    Karadas, B
    Duran, B
    Cetin, M
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2004, 94 (01) : 19 - 24
  • [48] EFFECT OF SOLUBLE GUANYLATE CYCLASE MODULATORS, BAY 60-2770 AND BAY 41-2272 IN ISOLATED CORPUS CAVERNOSUM FROM NORMOTENSIVE AND SPONTANEOUSLY HYPERTENSIVE RATS
    Estancial, C.
    Antunes, E.
    Rodrigues, R.
    Barbosa, A.
    Monica, F.
    JOURNAL OF SEXUAL MEDICINE, 2015, 12 : 52 - 53
  • [49] The guanylate cyclase stimulator BAY 41-2272 does not prevent right ventricular hypertrophy and failure alone or in combination with sildenafil
    Andersen, A.
    Nielsen, J. M.
    Holmboe, S.
    Vildbrad, M. D.
    Nielsen-Kudsk, J. E.
    EUROPEAN HEART JOURNAL, 2012, 33 : 113 - 113
  • [50] Administration of BAY 41-2272 prevents bladder dysfunction in nitric-oxide deficient rats
    Levi D'Ancona, Carlos Arturo
    Taufic Monica, Fabiola Zakia
    Reges, Ricardo
    Cohen, David
    da Silva, Fabio Henrique
    De Nucci, Gilberto
    Antunes, Edson
    EINSTEIN-SAO PAULO, 2010, 8 (04): : 404 - 409